

ISPOR 12TH ANNUAL EUROPEAN CONGRESS
24-27 OCTOBER 2009, Paris

IP5: PATIENT-REPORTED OUTCOMES AS A STANDARD APPROACH FOR HEALTH CARE POLICY MAKERS

Moderator: Andrew Bottomley PhD, Assistant Director, Head Quality of Life Department, EORTC, Brussels, Belgium

Panelists: Chantal Quinten MSc, Researcher, Quality of Life Department, EORTC, Brussels, Belgium; **Carolyn Gotay PhD**, Professor, University of British Columbia, Vancouver, BC, Canada

ISSUE: The panelists will use their extensive knowledge in quality of life to make researcher aware why (regulatory point of view) and how (different implementation strategies) to incorporate Patient-Reported Outcomes (PRO) from international cancer clinical trials in their health economic evaluations. They will use novel results from the EORTC PROBE project to demonstrate the added value of PRO in clinical decision making.

OVERVIEW: Cancer clinical trials have traditionally assessed clinical end points such as overall survival or progression-free survival. Incorporating PRO has received increasing attention over recent years. Our session will address the views of the FDA, EMEA and EORTC of the rising interest of PRO in oncology and the series of measures and policies these institutions have established. Additionally, we will compare implementation strategies from different groups to enhance PRO and which lessons can be learnt from them to improve PRO assessment. Finally, the session will use new and novel results gained from the EORTC Patient Reported Outcomes and Behavioural Evidence (PROBE) research program to demonstrate the value of PRO alongside clinical information for health care professionals. It will provide the audience with some tools in how to collect, analyse and interpret PRO data gathered from randomized controlled trials. Adequate collection and interpretation become imperative as it becomes more and more expensive to conduct clinical trials. We will encourage the audience to share their experience, debate with the presenters and help set future priorities for PRO assessment in the oncology outcome research field.